These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17380212)

  • 1. Mecasermin rinfabate.
    Kemp SF
    Drugs Today (Barc); 2007 Mar; 43(3):149-55. PubMed ID: 17380212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
    Kemp SF
    BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mecasermin rinfabate.
    Kemp SF; Fowlkes JL; Thrailkill KM
    Expert Opin Biol Ther; 2006 May; 6(5):533-8. PubMed ID: 16610982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
    Kemp SF; Thrailkill KM
    Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mecasermin.
    Keating GM
    BioDrugs; 2008; 22(3):177-88. PubMed ID: 18481900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
    Williams RM; McDonald A; O'Savage M; Dunger DB
    Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mecasermin Tercica.
    Norman P
    Curr Opin Investig Drugs; 2006 Apr; 7(4):371-80. PubMed ID: 16625824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SomatoKine: is there a use in treating growth disorders?
    Kemp SF; Thrailkill KM
    Curr Opin Investig Drugs; 2005 Apr; 6(4):373-7. PubMed ID: 15898344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
    Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
    J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
    Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
    Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mecasermin: new drug. Insufficient improvement in statural growth.
    Prescrire Int; 2009 Jun; 18(101):111-3. PubMed ID: 19637420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-I increases astrocyte intercellular gap junctional communication and connexin43 expression in vitro.
    Aberg ND; Blomstrand F; Aberg MA; Björklund U; Carlsson B; Carlsson-Skwirut C; Bang P; Rönnbäck L; Eriksson PS
    J Neurosci Res; 2003 Oct; 74(1):12-22. PubMed ID: 13130502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.